These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767 [TBL] [Abstract][Full Text] [Related]
43. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Ruan Z; Yang Z; Wang Y; Wang H; Chen Y; Shang X; Yang C; Guo S; Han J; Liang H; Wu Y J Immunother; 2009 Jun; 32(5):486-91. PubMed ID: 19609240 [TBL] [Abstract][Full Text] [Related]
44. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534 [TBL] [Abstract][Full Text] [Related]
45. [An experimental research on tumor metastasis treated by chicken homologous matrix metalloproteinase-2 vaccine combined with low-dose cisplatin]. Chen J; Hui XH; Li H; Cai BW; Wang W; Zhu B Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):35-9. PubMed ID: 17294723 [TBL] [Abstract][Full Text] [Related]
46. Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine. Wang H; Wang D; Li M; Zhou C; Ma W; Su X; Liu R; Zhang S Cancer Lett; 2008 Sep; 268(1):129-36. PubMed ID: 18468787 [TBL] [Abstract][Full Text] [Related]
47. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen. Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741 [TBL] [Abstract][Full Text] [Related]
48. [Suicidal cancer vaccine enhances anti-tumor immunotherapeutic effect and its safety in the treatment of ovarian cancer]. Kang Y; Xu CJ; Liu XS; Shao ZM; Ou ZL; Luo JM; Wu CQ; Zhong CP; Gu JR Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):654-7. PubMed ID: 17274368 [TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice. Chou B; Hiromatsu K; Okano S; Ishii K; Duan X; Sakai T; Murata S; Tanaka K; Himeno K J Immunol; 2012 Aug; 189(4):1618-26. PubMed ID: 22802414 [TBL] [Abstract][Full Text] [Related]
50. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373 [TBL] [Abstract][Full Text] [Related]
51. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
52. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269 [TBL] [Abstract][Full Text] [Related]
53. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075 [TBL] [Abstract][Full Text] [Related]
54. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Lou YY; Wei YQ; Yang L; Zhao X; Tian L; Lu Y; Wen YJ; Liu F; Huang MJ; Kang B; Xiao F; Su JM; He QM; Xie XJ; Mao YQ; Lei S; Liu JY; Lou F; Zhou LQ; Peng F; Jiang Y; Hu B Immunol Invest; 2002 Feb; 31(1):51-69. PubMed ID: 11990463 [TBL] [Abstract][Full Text] [Related]
55. The complete preventive effect of homologous tumor vaccines--based on a 5-year experimental study in mice. Tong X; Wang L; Liu Y; Qi Y; Qin Y; Xu Y; Tong T Biomed Pharmacother; 2010 Nov; 64(9):605-8. PubMed ID: 20961730 [TBL] [Abstract][Full Text] [Related]
56. Anti-angiogeneic target therapy for cancer with vaccine based on the recombinant chicken FGFR-1 in tumor-bearing mice. Zheng S; Zhang J; Zheng S; Huang F; Wu R; Cao L; Xie M J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):120-3. PubMed ID: 17497274 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of subcutaneous growth of Ehrlich ascites carcinoma (EAC) tumor by post-immunization with EAC-cell gangliosides and its anti-idiotype antibody in relation to tumor angiogenesis, apoptosis, cell cycle and infiltration of CD4+, CD8+ lymphocytes, NK cells, suppressor cells and APC-cells in tumor. Mondal B; Saha S Indian J Exp Biol; 2011 Aug; 49(8):574-84. PubMed ID: 21870425 [TBL] [Abstract][Full Text] [Related]
58. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565 [TBL] [Abstract][Full Text] [Related]
59. Administration of heat shock protein 65 inhibits murine melanoma growth in vivo. Yang J; Xie Y; Wang H; Yao Y; Hou J; Ma Y; Zhang Q; Xing Y; Wu J; Li T; Zheng J; Liu J; Cao R Mol Med Rep; 2013 Jan; 7(1):171-6. PubMed ID: 23135134 [TBL] [Abstract][Full Text] [Related]
60. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin. Zhao Z; Yao Y; Ding Z; Chen X; Xie K; Luo Y; Zhang J; Chen X; Wu X; Xu J; Zhao J; Niu T; Liu J; Li Q; Zhang W; Wen Y; Su J; Hu B; Bu H; Wei Y; Wu Y Vaccine; 2011 Jun; 29(25):4218-24. PubMed ID: 21497630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]